Laura Davidson, MD
Interventional Cardiology · Chicago, ILNPI 1003100280
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (54.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 79.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $1,374 and has fallen 92.8% since, to $98 in 2025. That places this record below the midpoint for interventional cardiology clinicians in IL, where the typical reported total is $7,434.
Across 24 payments — averaging $101.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Cardiva Medical, Inc.$349
- W. L. Gore & Associates, Inc.$73
- Abbott$26
- Heartflow, Inc.$23
- Inari Medical, Inc.$22
- plus $17 from 1 others
Across 17 payments — averaging $38,762 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$659K
What the payments were for
- Travel & lodging$1,32654%
- Food & beverage$1,10345%
- Education$171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 12 | $1,936 |
| Cardiva Medical, Inc. | 5 | $349 |
| W. L. Gore & Associates, Inc. | 3 | $73 |
| Abbott | 1 | $26 |
| Heartflow, Inc. | 1 | $23 |
| Inari Medical, Inc. | 1 | $22 |
| Amgen | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,447 in reported general payments places this provider in the 20th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $41,250 |
| Repatha SureclickEvolocumab | 30 | $20,485 |
| XareltoRivaroxaban | 11 | $14,395 |
| BrilintaTicagrelor | 11 | $9,008 |
| Repatha SyringeEvolocumab | 12 | $6,551 |
| Atorvastatin Calcium | 212 | $2,914 |
| Metoprolol Succinate | 144 | $2,552 |
| Ezetimibe | 68 | $2,083 |
| ClopidogrelClopidogrel Bisulfate | 67 | $1,227 |
| Amlodipine Besylate | 127 | $1,124 |
| Rosuvastatin Calcium | 62 | $1,041 |
| Lisinopril | 63 | $744 |
| Valsartan | 11 | $511 |
| Losartan Potassium | 46 | $508 |
| Carvedilol | 40 | $432 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Chicago
- Atman ShahChicago$788K
- David StewartChicago$169K
- Hussam SuradiChicago$97K
- Anita AsgarChicago$85K
- Daniel SchimmelChicago$79K
- Ranya SweisChicago$62K
- Charles DavidsonChicago$62K
- Fareed Moses ColladoChicago$42K
- James FlahertyChicago$38K
- Ashvarya ManglaChicago$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.